Lilly inks up to $1.93B autoimmune therapies deal with Repertoire
Eli Lilly has signed a strategic collaboration and licensing agreement with Repertoire Immune Medicines worth up to $1.93 billion to develop and commercialize programmable immunology therapies across multiple autoimmune diseases. The deal grants Lilly global rights to Repertoire’s recombinase platform enabling precise DNA insertions independent of natural repair mechanisms.
1. FDA Pushes Orforglipron Decision into Q2
The FDA has moved its target action date for Eli Lilly’s novel oral weight-loss candidate, orforglipron, by nearly two weeks, shifting the decision window from late April into early May 2026. Orforglipron is projected to address a $35 billion obesity market and analysts estimate peak annual sales could exceed $8 billion by 2030. The delay, while modest, increases uncertainty around the timing of a potential launch and could compress Lilly’s first-year revenue guidance for the product by as much as $150 million if approval is not granted before Q2 earnings season.
2. Wall Street’s Q4 Metrics Forecast Highlights Margin Pressure
Consensus estimates for Lilly’s quarter ended December 2025 call for revenue of $8.7 billion, up 11% year-over-year, and adjusted EPS of $2.15, representing a 9% increase. Investors are watching gross margin projections, currently pegged at 75%, down from 77% a year ago, reflecting higher launch costs for new therapies. R&D spending is expected to rise 15% to $3 billion, driven by late-stage trials in immunology and oncology, while SG&A expenses are forecast at $2.5 billion, up 8%, as marketing ramps for tirzepatide and other GLP-1 candidates.
3. $1.93 B Immunology Collaboration with Repertoire
Lilly has entered a strategic partnership with Repertoire Immune Medicines, securing rights to develop and commercialize multiple autoimmune therapies. The deal provides Repertoire with $200 million up front, $250 million in near-term milestones, and up to $1.48 billion tied to clinical, regulatory, and sales achievements. This transaction expands Lilly’s pipeline in rheumatoid arthritis and inflammatory bowel disease, potentially adding three inflammation assets to its 2026 development roster.
4. AI Supercomputer and Drug Discovery Lab with Nvidia
Eli Lilly and Nvidia have formed a co-innovation lab to deploy Nvidia’s BioNeMo platform and a purpose-built AI supercomputer at Lilly’s Indianapolis campus. The initiative will leverage Lilly’s clinical trial data—over 25 million patient records—and Nvidia’s GPUs to accelerate small-molecule design and predictive biomarker modeling. Management expects the AI capabilities to reduce candidate screening timelines by 30% and cut preclinical costs by $200 million annually once fully operational in H2 2026.